Close
Enter your
text here

Immunotherapy

Oncolytic Viroimmunotherapy Improved by Enhanced Cytokine Transgene Expression
 Oncolytic Viroimmunotherapy Improved by Enhanced Cytokine Transgene Expression 1024 575 Lauren Dembeck
By: Lauren Dembeck

Researchers were able to suppress in vivo tumor growth with an oncolytic virus by enhancing the production of the cytokine interleukin-12 in the tumors. Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive sarcomas that exhibit resistance to non-surgical treatment and have high rates of metastasis and relapse. The prognosis for MPNSTs is poor, with…

Novel Immunotherapy Approach Enhances Immune Surveillance in Gliomas
 Novel Immunotherapy Approach Enhances Immune Surveillance in Gliomas 1024 575 Lauren Dembeck
By: Lauren Dembeck

Genetically engineered myeloid cells release interleukin-2, which helps the immune system overcome the immunosuppressive tumor microenvironment in gliomas.   Gliomas — tumors originating from the neuronal support (glial) cells of the central nervous system — are one of the leading causes of cancer-related death in adolescents and young adults. Approximately two-thirds of gliomas in these…

Oncolytic Virus Immunotherapy Safe and Tolerable in Children With Relapsed or Refractory Solid Tumors
 Oncolytic Virus Immunotherapy Safe and Tolerable in Children With Relapsed or Refractory Solid Tumors 1024 683 Lauren Dembeck
By: Lauren Dembeck

The overall survival rates for children with childhood cancers is now over 80%; however, for children with relapsed and refractory tumors, the survival rates remain low. “For example, children with relapsed or refractory neuroblastoma have a five-year survival of less than ten percent,” explains Keri A. Streby, MD, director of the Neuroblastoma Program in the…